BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Endothelial cell
,
Personalized medicine
,
Quercetin
,
rs6983267
,
CXCL2
,
Apoptosis
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
neurokinin 3 receptors
Summary
General Info
Curated Studies
Most Correlated Studies
Monocytes (CD16+/-) from blood of HIV- donors treated with NK1R cognate ligand substance P
Explore Curated Studies Results
Literature
Most Relevant Literature
Tacr3/NK3R: Beyond Their Roles in Reproduction.
Lack of a genetic risk continuum between pubertal timing in the general population and idiopathic hy…
A single-nucleotide polymorphism induced alternative splicing in Tacr3 involves in hypoxic-ischemic …
A novel antidiuretic hormone governs tumour-induced renal dysfunction.
Interplay between hippocampal TACR3 and systemic testosterone in regulating anxiety-associated synap…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for t…
To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine…
Tachykinin and Kisspeptin Expression in Human Granulosa and Cumulus Cells
Neurokinin Receptor Antagonist Associated to Ondansetron in PONV
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bull…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ